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Pre-eclampsia is a vascular disorder of pregnancy where anti-angiogenic factors, systemic inflammation and oxidative stress
predominate, but none can claim to cause pre-eclampsia. This review provides an alternative to the ‘two-stage model’ of
pre-eclampsia in which abnormal spiral arteries modification leads to placental hypoxia, oxidative stress and aberrant maternal
systemic inflammation. Very high maternal soluble fms-like tyrosine kinase-1 (sFlt-1 also known as sVEGFR) and very low
placenta growth factor (PlGF) are unique to pre-eclampsia; however, abnormal spiral arteries and excessive inflammation are
also prevalent in other placental disorders. Metaphorically speaking, pregnancy can be viewed as a car with an accelerator
and brakes, where inflammation, oxidative stress and an imbalance in the angiogenic milieu act as the ‘accelerator’. The
‘braking system’ includes the protective pathways of haem oxygenase 1 (also referred as Hmox1 or HO-1) and
cystathionine-γ-lyase (also known as CSE or Cth), which generate carbon monoxide (CO) and hydrogen sulphide (H2S)
respectively. The failure in these pathways (brakes) results in the pregnancy going out of control and the system crashing. Put
simply, pre-eclampsia is an accelerator–brake defect disorder. CO and H2S hold great promise because of their unique ability
to suppress the anti-angiogenic factors sFlt-1 and soluble endoglin as well as to promote PlGF and endothelial NOS activity.
The key to finding a cure lies in the identification of cheap, safe and effective drugs that induce the braking system to keep
the pregnancy vehicle on track past the finishing line.
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L-arg, L-arginine; PAG, DL-propargylglycine; PlGF, placenta growth factor; RUPP, reduced uterine perfusion pressure;
sEng, soluble endoglin; sVEGFR-1 (also known as sFlt-1, soluble fms-like tyrosine kinase-1; StAmP, pravastatin to
ameliorate early-onset pre-eclampsia
BJP British Journal ofPharmacology
DOI:10.1111/bph.12977
www.brjpharmacol.org
1574 British Journal of Pharmacology (2015) 172 1574–1586 © 2014 The Authors. British Journal of Pharmacology published by John Wiley &
Sons Ltd on behalf of The British Pharmacological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Introduction
Pre-eclampsia is a major cause of maternal death worldwide
(Lowe et al., 2009). It is characterized by the onset of new
hypertension with proteinuria after 20 weeks of gestation.
There are no effective pharmacological agents to treat pre-
eclampsia. The only solution is the premature termination of
the pregnancy. Although maternal symptoms appear to be
largely resolved with the delivery of the baby, a growing body
of evidence indicates that pre-eclampsia is associated with
long-term health issues for both mother and baby (Smith
et al., 2001; Bellamy et al., 2007; MacDonald et al., 2007). The
human placenta is central to the development of pre-
eclampsia. The incidence of pre-eclampsia increases as preg-
nancy proceeds from singleton to twin, triplets and
quadruplets as the mass of placenta increases. Pre-eclampsia
also occurs in molar pregnancies further indicating that it is
the placenta and not the fetus that causes the condition. This
condition is still being debated as a ‘disease of theories’ as we
are entering into the second half of the second decade of the
21st century. In this review, we hope to shed new light and
provide a clear steer where researchers need to focus if we are
to find a cure for this elusive disorder in the first quarter of
this century.
Re-evaluation of existing theories
of pre-eclampsia
Abnormal spiral artery remodelling was first postulated over
five decades ago (Brosens, 1964; 1977) and has been accepted
as the underlying cause of pre-eclampsia (Khong et al., 1986;
Feinberg et al., 1991; Brosens et al., 2002; Burton et al., 2009).
Referred to as the two-stage process (Redman, 1992; Redman
and Sargent, 2005; Roberts and Hubel, 2009), for over two
decades, most researchers have argued that the development
of pre-eclampsia stems from abnormal spiral artery modifica-
tion leading to placental hypoxia, increase in oxidative stress
and aberrant maternal systemic inflammatory responses
(Naljayan and Karumanchi, 2013).
Recent studies have shown that such defects are not spe-
cific to pre-eclampsia (Lyall et al., 2013), and are also associ-
ated with placental abruption, preterm premature rupture of
membranes and intrauterine fetal death (Avagliano et al.,
2011), indicating that abnormal spiral artery remodelling
may be a common underlying contributing factor for abnor-
mal placentation, but is not specific to pre-eclampsia. Addi-
tionally, the immune-deficient Rag2−/−/γc−/− double-knockout
mice that lack spiral artery remodelling exhibit no pre–
eclampsia-like phenotype. Burke et al. concluded that neither
gestational hypertension nor deficient placental growth was
an outcome of impaired spiral artery remodelling (Burke
et al., 2010). Moreover, pre-eclampsia may occur in twin preg-
nancy despite normal uterine artery velocity waveform (Rizzo
et al., 1993). Finally, a meta-analysis on the performance of
first trimester uterine artery Doppler showed similar predic-
tive accuracy for pre-eclampsia and other complications such
as stillbirths and abruption (Velauthar et al., 2014). The test
had high specificity, but low sensitivity, and this pattern of
performance was noticed across various conditions including
pre-eclampsia. This once again indicates that the shallow
trophoblastic invasion in the spiral arteries resulting in pro-
gressive utero-placental ischaemia may relate to a more
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generalized remodelling pathology and is not the initiator of
pre-eclampsia per se (Burke and Karumanchi, 2013).
The concept that abnormal spiral artery remodelling
leading to hypoxia to support the two-stage hypothesis is
further challenged by other sets of data. Huppertz and col-
leagues report that failure of endovascular trophoblast inva-
sion does not lead to hypoxia. Rather, all measurements
available to date point to increased oxygen levels within the
placenta in patients with a failure of spiral artery transforma-
tion (Huppertz et al., 2014). Moreover, elevated soluble fms-
like tyrosine kinase 1 (sVEGFR-1 also known as sFlt-1) from
pre-eclamptic placenta is unlikely to be due to hypoxia per se
as pre-eclamptic placenta continues to generate substantially
higher levels of sVEGFR-1, even after 24 h of culture ex vivo
under atmospheric condition as compared with normal pla-
cental explants under identical experimental conditions
(Ahmad and Ahmed, 2004). If we accept that the clinical
signs of pre-eclampsia are due, in large part, to elevated levels
of sVEGFR-1, these findings challenge the long held belief
that pre-eclampsia arises because of placental hypoxia. Based
on these studies, we argue that the failed remodelling of
maternal spiral arteries leading to hypoxia has been miscon-
ceived, for many years, as the cause of pre-eclampsia.
Another theory that has long been adopted without con-
vincing clinical evidence is the idea that an elevation in
maternal systemic inflammation is the cause of pre-eclampsia
(Redman et al., 1999). Although studies in rodents support
the systemic maternal inflammatory response and placental
ischaemia hypothesis (LaMarca et al., 2007; Cotechini et al.,
2014), this is not supported by human cytokine data. In
human pregnancy, the elevation in pro-inflammatory status
does not seem to precede the onset of pre-eclampsia
(Djurovic et al., 2002; Kronborg et al., 2011; Carty et al.,
2012). Furthermore, it is not associated with the severity of
the disorder as there is no observed significant difference
among serum TNF-α and IL-6 levels in patients with mild
pre-eclampsia, severe pre-eclampsia and hemolysis, elevated
liver enzymes, low platelets syndrome in pre-eclampsia (Ozler
et al., 2012). Moreover, pregnant women with elevated sys-
temic inflammation had increased IL-6 levels, but normal
angiogenic status without exhibiting symptoms of hyperten-
sion or proteinurea (Ramma et al., 2012). More importantly, a
prospective longitudinal study of 2600 women with single-
ton pregnancies who went on to develop pre-eclampsia using
multiplex analysis of inflammatory markers and cytokines
showed that there was no increase in any of the cytokines
before the onset of pre-eclampsia (Carty et al., 2012). In addi-
tion, antenatal corticosteroid treatment demonstrated that
inflammation is unlikely to be the major contributor to
severe pre-eclampsia or useful for therapeutic targeting
(Nayeri et al., 2014). These findings weaken the hypothesis
that inflammation is the cause of pre-eclampsia.
Is endothelial activation the
central phenomenon?
Maternal endothelial dysfunction is the central phenomenon
responsible for the clinical signs of pre-eclampsia. Soluble
E-selectin, a marker of endothelial cell activation, was found
to be significantly higher at 12–16 weeks gestation in women
who subsequently developed pre-eclampsia (Carty et al.,
2012). One of the theories postulated to be responsible for
maternal endothelial dysfunction is the excessive production
of free radicals (Wickens et al., 1981; Tsukatani, 1983; Roberts
et al., 1989; Davidge, 1998; Hubel, 1999). This theory led
obstetricians and scientists to advocate that maternal supple-
mentation with low-dose aspirin or antioxidants could
reduce oxidative stress (Wallenburg et al., 1986; Schiff et al.,
1990; Kharb, 2000; Poston et al., 2006). These studies were
undertaken without clear mechanistic evidence as daily
intake of vitamin C, for just 6 weeks, increases the plasma
level of 8-oxoadenine, a marker for DNA damage mediated by
oxygen radicals (Podmore et al., 1998). Subsequent extensive
systematic reviews with meta-analysis revealed that there is
little evidence to support the administration of low-dose
aspirin or vitamins C and E for either high- or low-risk
women to prevent pre-eclampsia (Rossi and Mullin, 2011;
Villa et al., 2013). There may be some benefit in the reduction
of perinatal death and other adverse perinatal outcomes of
low-dose aspirin initiated before 16 weeks of gestation
(Roberge et al., 2013).
In the last decade, the hypothesis that pre-eclampsia arise
because of the loss of VEGF activity as a result of the ‘increase
in the levels of endogenous soluble (s)VEGFR-1 (also known as
sFlt-1) that may antagonize the beneficial effects of VEGF’
(Ahmed, 1997), has been validated. A number of studies have
consistently shown that the imbalance in anti-angiogenic
factors is most strongly associated with the clinical signs of
pre-eclampsia and disease severity (Chappell et al., 2002; 2013;
Maynard et al., 2003; Ahmad and Ahmed, 2004; Buhimschi
et al., 2006; Crispi et al., 2006; Levine et al., 2006; Venkatesha
et al., 2006; Ramma et al., 2012). Anti-angiogenic factors,
sVEGFR-1 and soluble endoglin (sEng, also known as CD105)
are increased before the clinical onset of pre-eclampsia (Levine
et al., 2006), and pregnant rodents exposed to high circulating
levels of sVEGFR-1 illicit severe pre–eclampsia-like symptoms
(Ramma and Ahmed, 2011; Rana et al., 2014).
Metaphorical view of pre-eclampsia
Metaphorically speaking pregnancy can be seen as a car with
an accelerator and brakes, where inflammation, oxidative
stress and an imbalance in the angiogenic milieu act as
‘accelerators’. It is the failure in the braking systems, the
endogenous protective pathway, that result in the ‘accelera-
tor’ going out of control until the system crashes, manifest-
ing itself as pre-eclampsia (http://youtube/vWUCWbKo1dE).
The identification of the braking system and how to enhance
the brakes when the system starts to fail can restore balance
and possibly cure pre-eclampsia. The strategy to identify a
cure for pre-eclampsia needs to be centred on identifying
cytoprotective pathways, which reduce sVEGFR-1, sEng, oxi-
dative stress and inflammation. The study of enzyme
systems, which generate gasotransmitters, has the potential
to lead to the discovery of effective treatments for pre-
eclampsia. The trial that uses pravastatin to ameliorate early-
onset pre-eclampsia (StAmP) is the first such approach
underway in the UK; similarly other clinical trials are now
taking place in the USA and Australia.
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Endogenous cytoprotective pathway
While most laboratories focused on finding the ‘accelerators’
of pre-eclampsia, our laboratory switched our efforts to iden-
tify key endogenous protective pathways; the control switch
for the ‘accelerators’. The first ‘brake’ system identified was
the haem oxygenase (HO)/carbon monoxide (CO) pathway
(Ahmed et al., 2000). Recently, another ‘brake’ system discov-
ered was the cystathionine-γ-lyase (CSE also known as Cth)
(Wang et al., 2013), which produces hydrogen sulphide (H2S)
(Bir and Kevil, 2013). These protective pathways inhibit
sVEGFR-1 and sEng release (Cudmore et al., 2007; Wang et al.,
2013) making them good candidates for the ‘brake’ theory
outlined in Figures 1 and 2.
Gasotransmitters
Gaseous signalling molecules, such as NO, CO and H2S, have
all been hailed as promising molecules with clinical thera-
peutic potential largely because of their ability to act as vaso-
dilators (Moncada, 1997; Dulak et al., 2008; Bir and Kevil,
2013). The enzyme systems that generate NO, CO and H2S are
able to promote placental vasodilatation by regulating pla-
cental blood vessel tone in vitro and in vivo (Gude et al., 1990;
Myatt et al., 1991; Gonzalez et al., 1995; Learmont and
Poston, 1996; Odrcich et al., 1998; Ahmed et al., 2000;
Bainbridge et al., 2002; Zhao et al., 2008; Patel et al., 2009;
Holwerda et al., 2012; Cindrova-Davies et al., 2013; Wang
et al., 2013). The discovery that NO, CO or H2S can promote
placental blood flow is not surprising as these molecules have
been shown to do this in a number of other vascular beds
(Mustafa et al., 2009; Coletta et al., 2012). This property of
these gaseous molecules by themselves is of limited therapeu-
tic value in suppressing pre-eclampsia as illustrated by
numerous NO studies (Johal et al., 2014). However, it is the
additional properties of CO and H2S that makes them an
attractive proposition in the search to identify therapies that
would prevent pre-eclampsia.
HO/CO system
HO is the rate-limiting enzyme responsible for the degrada-
tion of haem in the endoplasmic reticulum to generate equi-
molar amounts of biliverdin, free iron and CO (Tenhunen
et al., 1969). Biliverdin is rapidly reduced to bilirubin, a
potent antioxidant, by the cytosolic enzyme biliverdin reduc-
tase. CO is a potent vasodilator and also has anti-apoptotic
properties. HO exists in two main isoforms, HO-1 and HO-2.
The enzyme HO-2 is a 36 kDa protein that is constitutively
expressed at high concentrations in the brain, testis and
vascular endothelium. The inducible form, HO-1 is a 32 kDa
protein that is widely distributed in the body, with high
concentrations in the liver and the spleen. In mammalian
tissues, HO-1 is induced by its substrate haem and also by
heavy metals. Furthermore, stimuli that cause oxidative
stress, such as peroxynitrite, modified lipids, hypoxia, hyper-
oxia, ischaemia/reperfusion, hyperthermia and endotoxic
shock, up-regulate the expression of HO-1 (Sikorski et al.,
Figure 1
Effect of defective protective pathways in pre-eclampsia. This diagram illustrates that the defect in HO-1 (also referred to as Hmox) and CSE (also
known as Cth), which generates signalling molecules, CO and H2S, and which results in an increase in sVEGFR-1 and sEng as well as a decrease
in PlGF production. These are key factors responsible for vascular dysfunction in pre-eclampsia.
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2004). HO-1 via its products inhibits oxidative stress, inflam-
mation and apoptosis (Dulak et al., 2008). A deficiency of
HO-1 in humans results in severe and persistent endothelial
damage as indicated by the marked elevation in thrombo-
modulin and von Willebrand factor (Yachie et al., 1999).
HO/CO cytoprotective pathway
in pregnancy
HO-1 and CO play a role in the maintenance of uterine
quiescence during human pregnancy (Acevedo and Ahmed,
1998) and in modulating the utero-placental circulation
(Ahmed et al., 2000; Lyall et al., 2000). More importantly,
placental HO protected human placenta from cellular
damage (Ahmed et al., 2000). A recent murine study showed
that CO acts as a key molecule in successful pregnancy by
modulating the uterine NK cells, which result in the promo-
tion of the remodelling of maternal spiral arteries (Linzke
et al., 2014). Decreased expression of HO has also been asso-
ciated with human pregnancy disorders such as recurrent
miscarriages (Denschlag et al., 2004), intrauterine growth
retardation (Wong et al., 2012) and pre-eclampsia (Ahmed
et al., 2000; Barber et al., 2001).
In pre-eclampsia, the functional importance of HO gained
traction after the publication, which demonstrated that
adenoviral HO-1 overexpression or CO exposure reduced
sVEGFR-1 release from endothelial cells, while siRNA-
mediated HO-1 knockdown increases sVEGFR-1 release
(Cudmore et al., 2007). A small, but significant clinical study
subsequently showed that the HO-1 mRNA was decreased in
the chorionic villous (fetal placental cells) sampled at 11
weeks of gestation in women who went on to develop pre-
eclampsia compared with normal pregnancies (Farina et al.,
2008). Also, the addition of pre-eclampsia sera to the tropho-
blast increases sEng release and inhibits HO-1 expression
(Aoki et al., 2012). Further support for HO-1 acting as a nega-
tive regulator of anti-angiogenic factors comes from a recent
clinical study demonstrating that in samples of villous
trophoblast obtained from women between 6 and 11 weeks of
gestation undergoing elective abortion, the mRNA levels of
HO-1 were significantly increased with gestational age,
whereas the mRNA expression of sVEGFR-1 was significantly
decreased with increasing gestational age (Miyagami et al.,
2013). Finally, a recent study showed that the long allele of a
guanine–thymine polymorphism in the HO-1 promoter
region is associated with pre-eclampsia (Kaartokallio et al.,
2014). Poor vascular compliance maybe associated with long
allele. Collectively, these clinical studies reinforce our theory
that placental HO-1 is (i) protective (Ahmed et al., 2000) and
(ii) acts as a negative regulator of sVEGFR-1 and sEng
(Cudmore et al., 2007). These findings support our proposed
model of pre-eclampsia as an accelerator–brake defect disor-
der. Thus, we would argue that a partial loss of HO-1 activity
early in gestation maybe responsible for the cascade of events
that culminate in pre-eclampsia (Figure 2).
Interestingly another protective pathway appears to be
mediated via the HO-1 system. Kenny’s laboratory showed
that the administration of a PPAR-γ agonist prevented the
development of several of the pathophysiological character-
istics associated with the reduced uterine perfusion pressure
(RUPP) rat model of pre-eclampsia, via a HO-1-dependent
pathway (McCarthy et al., 2011). Finally, the pharmacologi-
cal induction of HO by cobalt protoporphyrin attenuates
placental ischaemia-induced hypertension in this RUPP
model (George et al., 2011) and the application of CO could
normalize BP in gestational hypertensive HO-1+/− pregnant
mice (Linzke et al., 2014).
Another hallmark of pre-eclampsia is glomerular endothe-
liosis, which results in poor filtration and increased protein in
the urine (Maynard et al., 2003). Apart from the administra-
tion of sVEGFR-1, VEGF neutralizing antibody to non-
pregnant rats also results in glomerular endothelial cell
Figure 2
The accelerator and brake theory of pre-eclampsia. Schematic
diagram to illustrate the sequence of events involved in the patho-
genesis of pre-eclampsia. The upstream events consist of dysregula-
tion of endogenous protective pathways – ‘the brakes’ – [CSE which
generates H2S and HO-1 that produces CO] leading to maternal
endothelial activation. As a consequence, there is an increase in
anti-angiogenic factors – ‘the accelerator’ – (sVEGFR-1, sEng and
soluble E-slectin and a decrease in angiogenic factors PlGF and
eNOS, which generates NO). These biochemical changes lead to a
generalized endothelial dysfunction, renal injury and generation of
reactive oxygen species, which precedes the clinical onset of pre-
eclampsia. After 20 weeks of gestation, the clinical symptoms mani-
fest themselves as high BP and proteinurea, which are concurrent
with excessive inflammation as indicated by increase in pro-
inflammatory cytokines (Th1 cytokine production) and ET-1 release.
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damage and proteinuria (Sugimoto et al., 2003). Cancer
patients receiving anti-VEGF therapy exhibit pre–eclampsia-
like symptoms, suggesting that decreased bioavailability of
VEGF causes these symptoms (Kabbinavar et al., 2003).
Unfortunately, the effect of loss of HO-1 activity on kidney
function in a pre-eclampsia setting is unknown and warrants
investigation.
CO paradox in pregnancy
The source of CO produced in the body, including in the
human placental chorionic villi, was shown to originate from
haem, primarily through the action of HO (Ahmed et al.,
2005). Women with pre-eclampsia have a significantly
reduced level of CO in their exhaled breath compared with
those with healthy pregnancies indicating a decreased in HO
activity (Baum et al., 2000; Kreiser et al., 2004). Interestingly,
smoking during pregnancy reduces the incidence of pre-
eclampsia, despite being associated with spontaneous abor-
tion, stillbirth, preterm labour, fetal growth restriction and
placental abruption (Conde-Agudelo et al., 1999). Smokers
are also known to have reduced levels of circulating sVEGFR-1
(Levine et al., 2006). The smoking paradox was explained by
the experimental observation that exposure to CO reduces
endothelial and placental sVEGFR-1 and sEng release
(Cudmore et al., 2007). Furthermore, cigarette smoke extract
was shown to induce the expression of HO-1 in placental
explants (Sidle et al., 2007) and decrease sVEGFR-1 release
from placental villous explants without affecting the placen-
tal apoptotic status (Mehendale et al., 2007). Taken together,
these studies showed that CO from cigarette smoke
accounted for the reduced incidence of pre-eclampsia in
smokers through the inhibition of sVEGFR-1 release
(Cudmore et al., 2007; Farina et al., 2008; Zhao et al., 2009;
Ahmed, 2011). The theory put forward in the May 2000 issue
of Molecular Medicine demonstrating that HO offers protec-
tion against placental cytotoxic damage associated with pre-
eclampsia appears to hold true, based on the supporting data,
which has emerged over the last decade. HO-1 is one of the
survival breaks against pre-eclampsia (Figure 2).
CSE/H2S system
H2S is a gaseous signalling molecule, which promotes
vasodilatation (Zhao et al., 2001), exhibits cytoprotective
anti-inflammatory properties (Zanardo et al., 2006), protects
against cellular damage induced by reperfusion injury
(Elrod et al., 2007) or lethal hypoxia (Blackstone and Roth,
2007), and stimulates angiogenesis in the vasculature
(Papapetropoulos et al., 2009). Endogenous H2S production is
regulated by three enzymes CSE (also known as Cth),
cystathionine-β-synthase (CBS) and 3-mercaptopyruvate sul-
furtransferase (MPST), and generated from the substrates cys-
tathionine, homocysteine, cysteine and mercaptopyruvate
respectively (Bir and Kevil, 2013). CBS is most abundantly
expressed in the brain (Kery et al., 1994) whereas CSE is the
principal enzyme responsible for the endogenous production
of H2S in the vasculature (Yang et al., 2008; Kabil et al.,
2011). Administration of the CSE selective inhibitor (DL-
propargylglycine, PAG) leads to elevated BP and vascular
remodelling in the rat (Yan et al., 2004) and H2S levels are
reduced in pulmonary hypertensive rats (Yanfei et al., 2006).
Mice lacking CSE develop age-dependent hypertension,
severe hyperhomocysteinaemia, and endothelial dysfunction
(Yang et al., 2008).
CSE/H2S pathway in pregnancy
The effects of low levels of H2S showed normal fetal growth
and development during pregnancy and it increased delivery
time in rats (Hayden et al., 1990) suggesting H2S may exhibit
tocolytic characteristics. Indeed H2S inhibits spontaneous
contractility in isolated pregnant rat uterine (Sidhu et al.,
2001) and human myometrial strips (Hu et al., 2011; You
et al., 2011; Robinson and Wray, 2012), similar to what was
reported for CO (Acevedo and Ahmed, 1998). This is an area
worthy of further investigation. Can myometrial-specific
changes in HO-1 or CSE influence parturition?
An H2S-producing system exists within the utero-
placental unit (Patel et al., 2009; You et al., 2011). For almost
10 years it has been know that both H2S and CO act as
vasodilators (Leffler et al., 2006). It is therefore reassuring that
perfusion of normal placenta with an H2S donor results in
vasorelaxation of preconstricted vasculature (Cindrova-
Davies et al., 2013). H2S may act as a vasodilator in the pla-
cental circulation as is the case for H2S in a number of other
vascular beds.
Recent immunohistochemical localization studies with
CSE and CBS reported contradictory findings on placental
pathologies. Holwerda and colleagues observed no changes in
CSE expression, but a decrease in CBS expression in placenta
from severe pre-eclampsia (Holwerda et al., 2012). In contrast,
CSE immunoreactivity was reduced in placenta from preg-
nancies with severe early-onset growth-restriction and pre-
eclampsia (Cindrova-Davies et al., 2013; Wang et al., 2013).
Real-time PCR confirmed reduced CSE mRNA in pre-
eclamptic women and it was associated with decreased levels
of plasma H2S (Wang et al., 2013). However, these observa-
tional studies provide little insight into the contributing
role of this enzyme system or its gaseous product in
pre-eclampsia.
Given that the placenta is a highly vascular organ, Wang
et al. proposed that the dys-regulation of the CSE/H2S
pathway would promote placental abnormalities and contrib-
ute to a pre–eclampsia-like condition. Like the HO-1 system,
which negatively regulates sVEGFR-1 and sEng (Cudmore
et al., 2007), the CSE pathway has been shown to have similar
capabilities. Endothelial CSE knockdown by siRNA increased
the endogenous release of sVEGFR-1 and sEng while
adenoviral-mediated CSE overexpression inhibited their
release from endothelial cells. Furthermore, inhibition of CSE
activity by administration of PAG to pregnant mice induced
hypertension, liver damage, elevated sVEGFR-1 and sEng and
promoted abnormal labyrinth vascularization in the placenta
and decreased fetal growth. These symptoms were reversed
when the inhibitor was supplemented with GYY4137, a slow-
releasing H2S-generating compound demonstrating that the
effect of CSE inhibitor was due to inhibition of H2S produc-
tion (Wang et al., 2013). These findings imply that endog-
BJPGasotransmitters in pre-eclampsia
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enous H2S is required for healthy placental vasculature and a
decrease in CSE/H2S activity may contribute to the pathogen-
esis of pre-eclampsia. Indeed, H2S was also reported to protect
against acute myocardial ischaemia/reperfusion injury. Treat-
ment with H2S donor (SG-1002) offers cardioprotection via
up-regulation of the VEGF–Akt–NOS3–NO pathway (Kondo
et al., 2013).
The importance of H2S in preventing damage is further
supported by a recent study showing that H2S attenuates
adenovirus-mediated overexpression of sVEGFR-1-induced
hypertension and renal damage in non-pregnant Sprague
Dawley rats (Holwerda et al., 2014). This study also showed
that rat renal VEGF-A mRNA expression increased signifi-
cantly with intraperitoneal injection of H2S donor, sodium
hydrosulphide (NaHS) treatment and NaHS stimulated podo-
cytes in culture to release VEGF (Holwerda et al., 2014). H2S is
known to stimulate VEGF; exposure of vascular smooth
muscle cells to H2S up-regulates hypoxia inducible factor
(HIF)-1α and VEGF protein levels and increased HIF-1α
binding activity under hypoxic condition (Liu et al., 2010).
Recently, VEGFR-2 was reported as the direct target of H2S and
a VEGF receptor inhibitor suppressed angiogenesis induced
by H2S (Tao et al., 2013). These findings indicate that H2S
promotes angiogenesis via VEGF receptor activation.
Clearly, CSE may also play a key role in placental devel-
opment as inhibition of CSE activity by PAG inhibited tropho-
blast invasion in vitro (Wang et al., 2013). Inhibition of CSE
activity in early (first trimester) human placental explants
obtained from termination of pregnancy results in a marked
reduction in placenta growth factor (PlGF) production (Wang
et al., 2013). In pre-eclampsia, the maternal circulating level
of PlGF is decreased well before the onset of the symptoms
(Levine et al., 2004; 2006). Although the significance of this
decrease in PlGF remains to be explained in women, studies
by Kumasawa et al. and colleagues show that administration
of PlGF in lentiviral sVEGFR-1-infected mice depresses the
level of sVEGFR-1 and ameliorated hypertension, glomerular
endotheliosis and proteinuria in the mice (Kumasawa et al.,
2011). The loss of activity in the H2S-producing enzyme CSE
may account for the reduction in PlGF in pre-eclampsia
(Wang et al., 2013). As PlGF is one of the earliest maternal
circulating markers to be reduced in women destined to
develop early-onset pre-eclampsia (Chappell et al., 2002;
2013), CSE/H2S activity may be upstream to PlGF and could be
an earlier biomarker as well as a key regulator that keeps the
level of PlGF sufficiently high to counteract the deleterious
effect of sVEGFR-1, which can induce pre–eclampsia-like
symptoms if allowed to go unchecked.
Pharmacological studies using a PAG inhibitor have their
limitations because of off-target effects and have been shown
to inhibit other pyridoxal-5′-phosphate-dependent enzymes
(Whiteman et al., 2011); the lack of selectivity for specific
isozymes means future studies need to be carried out using
gene inactivation approaches by delineating CSE in the pla-
centa and maternal endothelium (Bir and Kevil, 2013).
NOS3/NO system
NO is synthesized from the nonessential amino acid
L-arginine (L-arg) by the enzyme NOS. There are three iso-
forms of NOS: NOS1 (neuronal), NOS2 (inducible) and NOS3
(endothelial). NOS1 and NOS3 are considered constitutive
(cNOS). The NO produced in endothelial cells induces vascu-
lar smooth muscle relaxation via a cGMP-dependent pathway
to promote vasodilatation. Other beneficial effects of NO in
the vascular system include inhibition of ET-1 and TxA2
production, platelet aggregation, leukocyte adhesion and
smooth muscle proliferation (Lowe, 2000). NO also inhibits
production of VCAM-1 and fibronectin as well as low-density
lipoprotein oxidation (Ahmed et al., 2009) and is critical for
neovascularization (Bussolati et al., 2001; Ahmad et al.,
2006).
Loss of endothelial NOS (NOS3) activity is an established
contributor to endothelial dysfunction (Heitzer et al., 2001).
NO is highly reactive as it has an unpaired electron, thus a
dynamic competition between superoxide and lipid radicals
for reaction with NO is inevitable. NO only stimulates
superoxide-dependent lipid oxidation when the production
rate of NO is less than superoxide (Rubbo et al., 2000). In
endothelial cells, NOS3 exists in a homodimeric complex that
is stabilized by the cofactor BH4. Decreased availability of
BH4 results in ‘uncoupling’ of NOS3 activity and increases
the production of superoxide (d’Uscio et al., 2001; Bendall
et al., 2005).
NOS3/NO pathway in pregnancy
Enzyme expression and localization studies by themselves
can be misleading. However, blocking the production of NO
by administering a NOS-inhibiting agent produces virtually
all the symptoms of pre-eclampsia in pregnant mice and rats
suggesting that the NOS pathway is a key player in this
disorder (Lowe, 2000). A meta-analysis showed that genetic
variations in the NOS3 gene contribute to an increased risk
for pre-eclampsia (Dai et al., 2013). Indeed BH4 doubled
NOS3 activity in a concentration-dependent manner in
homogenates of first trimester and term placenta (Kukor
et al., 2000) and uncoupled NOS3 and oxidative stress in a rat
model of pregnancy-induced hypertension (Mitchell et al.,
2007). However, BH4 concentrations in pre-eclamptic pla-
centa were reported to be comparable with those of normal
placenta (Kukor et al., 2000). In non-pregnant mice lacking
NOS3, the sVEGFR1-induced pre-eclampsia phenotype in
mice is aggravated (Li et al., 2012).
A nested case control study of screening for pre-eclampsia
revealed that asymmetric dimethylarginine (ADMA), arginine
and homoarginine at 11–13 weeks’ gestation did not change
in women who went on to develop late-onset pre-eclampsia,
but L-arg and homoarginine levels were decreased in those
who developed early-onset pre-eclampsia (Khalil et al., 2013).
Interestingly, maternal serum ADMA concentration tends to
increase during normal pregnancy, but ADMA concentrations
in the second trimester were significantly elevated in preg-
nancies that later developed pre-eclampsia (Rizos et al., 2012).
An important cause of impaired endothelial NO produc-
tion is the reduced availability of the NOS3 substrate L-arg. A
study reported that plasma nitrite and superoxide dismutase
activity were significantly lower while arginase activity and
plasma endothelin levels were significantly higher in pre-
eclamptic women than in normotensive pregnant women
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(Bernardi et al., 2008). Why arginase activity is increased
during pregnancy is unknown, but should be a subject of
future investigation. The Davidge laboratory have shown that
an increased arginase expression in pre-eclampsia can induce
the uncoupling of NOS as a source of superoxide in the
maternal vasculature in pre-eclampsia, and suggested that
L-arg supplementation in the face of oxidative stress could
lead to a further increase in peroxynitrite (Sankaralingam
et al., 2010). Thus, this brings into question L-arg supplemen-
tation as therapy without clear mechanistic evidence.
Maximum activity of NOS3 is achieved when the residue
S1177, which is targeted by Akt, is phosphorylated and
residue T497 is dephosphorylated. The constitutively active
NOS3 mutant, S1177D enhances NO-mediated relaxation of
bradykinin-stimulated porcine coronary arteries (Teupe et al.,
2002). Basal production of NO from cells is markedly reduced
in cells transfected with T497A and T497A/S1177D (TASD)
NOS3 because of the generation of more superoxide anion
that interact with NO. In contrast, NO production is aug-
mented in cells transfected with S1177D NOS3 (Lin et al.,
2003). Using adenoviruses expressing wild-type NOS3 and
S1177D and TASD NOS3 mutants, we discovered that neither
the constitutively active NOS3 mutant S1177D nor the TASD
NOS3 mutants suppress VEGF-induced sVEGFR-1 release
from endothelial cells. These unpublished findings are in
marked contrast to studies in which sildenafil citrate reduces
the plasma levels of sVEGFR-1 and sEng in L–NAME-treated
Sprague Dawley pregnant rats (Ramesar et al., 2011). Sildena-
fil may exert its effect indirectly. Finally, storkhead box 1
(STOX1) overexpression switches the free radical balance
from reactive oxygen species to reactive nitrogen species in
the placenta (Doridot et al., 2014), which may deprive mater-
nal NO and compromise blood flow or increase endothelial
dysfunction. Could this act as a genetic switch altering vas-
cular function and inhibiting the protective genes such as
HO-1?
Conclusion
Women destined to develop early-onset pre-eclampsia could
be offered therapies that up-regulate ‘the endogenous cyto-
protective pathway’. A cheap and widely available therapy
against pre-eclampsia may be on the horizon if pravastatin
(3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibi-
tors) proves to be ‘safe’ in randomized controlled trial (RCT)
(StAmP). Although statins are contraindicated in pregnancy,
the finding that statins inhibited sVEGFR-1 led to the UK
regulatory authorities approving the first RCT on statins in
pre-eclampsia. Today, there are two additional trials under-
way in Australia and the United States.
In order to develop additional therapies to tackle pre-
eclampsia, basic research is urgently needed to elucidate fully
the role of HO-1 and CSE and their metabolites. Murine
models do not equate to pre-eclampsia in women, but they
can replicate many of the pre-eclampsia symptoms. This
offers very useful tools to perform proof of principle experi-
ments to determine the role of specific genes and potential
new therapies. H2S or CO may modulate NOS3 activity to
prevent pre-eclampsia. It is established that one of the ben-
eficial effects of statins in the prevention of cardiovascular
events is their ability to enhance endothelial function by
increasing NOS3 expression and activity (Xenos et al., 2005).
The success of the StAmP trial may not only depend on its
ability to up-regulate HO or inhibit sVEGFR-1, but on the
power of statins to inhibit an array of stress factors associated
with pre-eclampsia.
This review suggests new investigations with new think-
ing which challenges the existing dogma, employs the use of
sophisticated inducible- and tissue-specific knockdown tools
in what we refer to ‘the maternal and fetal vascular compli-
cations mouse models of pre-eclampsia’ combined with
human clinical-based sample studies. For example, transcrip-
tion factor STOX1 overexpressing pregnant mice exhibit
symptoms of severe pre-eclampsia: gestational hypertension,
proteinuria, and elevated plasma levels of sVEGFR-1 (soluble
fms-like tyrosine kinase 1) and sEng (Doridot et al., 2013). We
propose a new paradigm as outlined here in ‘the accelerator
and brake’ hypothesis, which can encompass novel factors
(Figure 2). We need to design rigorous tests for a given
hypothesis and bring in a team-based approach, which can
utilize resources from a range of settings. Studies need to
encompass clinical samples, cell culture studies and proof of
concept mouse models as outlined earlier. The criticism of
mouse models in pre-eclampsia needs to stop, provided the
animal data are backed up by human data as illustrated in a
number of comprehensive studies (Maynard et al., 2003;
Wang et al., 2013). Animal studies in pre-eclampsia should be
accepted as powerful scientific tools where specific genes can
be delineated in a tissue-specific fashion to address specific
questions. We propose this approach for the cytoprotective
pathway gasotransmitter enzymes, which we believe holds
the greatest promise in the clinic and maybe to the underlin-
ing mechanism that is defective in pre-eclampsia. In conclu-
sion, our discovery of the two gasotranmitter enzyme systems
as protective pathways to treat or prevent preeclampsia
(Figure 1) and the accelerator-brake model of preeclampsia is
being used to develop new therapies, which aim to enhance
the brakes when the system starts to fail. The StAmP trial is
the first such approach to be completed. The future person-
alized pre-eclampsia therapy is looking promising!
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